Athersys: peers
Athersys beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Athersys, Brainstorm Cell Therapeutics Inc., Enzon Pharmaceuticals, Inc., Inhibikase Therapeutics, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Athersysbase ATHX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Brainstorm Cell Therapeutics Inc. BCLI · 🇺🇸 US Percentile in Healthcare Percentile in USA | Enzon Pharmaceuticals, Inc. EZ1.F · 🇺🇸 US Percentile in Healthcare Percentile in USA | Inhibikase Therapeutics, Inc. IQT.F · 🇺🇸 US Percentile in Healthcare Percentile in USA | Allarity Therapeutics, Inc. ALLR · 🇺🇸 US Percentile in Healthcare Percentile in USA | Valion Bio, Inc. VBIO · 🇺🇸 US Percentile in Healthcare Percentile in USA | aTyr Pharma, Inc. ATYR · 🇺🇸 US Percentile in Healthcare Percentile in USA | Vyome Holdings, Inc HIND · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $14 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one2nd of 8 | $14 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one2nd of 8 | $14 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one2nd of 8 | $14 Mlast known, Dec 25, 2022 · Market dataLast known value: no current one2nd of 8 | $14 MOct 15, 2026 · Market data6th of 8 | $14 MOct 30, 2026 · Market data7th of 8 | $14 MOct 30, 2026 · Market data8th of 8 | $14 MOct 7, 2026 · Market data1st of 8 | $14 M8 ranked |
| Revenue (Better neither way: ranked highest first) | $6 MFY2019 · Wikidata1st of 3 | —— | —— | —— | $0 MFY2025 · SEC2nd of 3 | —— | $0 MFY2025 · SEC3rd of 3 | —— | $0 M3 ranked |
| Net income (Higher is better) | —— | —— | $-3 MFY2025 · SEC1st of 6 | $-48 MFY2025 · SEC5th of 6 | $-11 MFY2025 · SEC4th of 6 | $-9 MFY2025 · SEC2nd of 6 | $-74 MFY2025 · SEC6th of 6 | $-10 MFY2025 · SEC3rd of 6 | $-11 M6 ranked |
| Employees (Better neither way: ranked highest first) | 832019 · Profile1st of 5 | 20December 31, 2025 · Profile4th of 5 | —— | —— | —— | 52December 31, 2025 · Profile3rd of 5 | 58December 31, 2025 · Profile2nd of 5 | 18December 31, 2025 · Profile5th of 5 | 525 ranked |
| Margins and returns | |||||||||
| Return on equity (Higher is better) | ———— | ———— | -4.6%FY2025 · SEC1st of 570th37th | -36.0%FY2025 · SEC2nd of 551st22nd | -103.8%FY2025 · SEC4th of 524th10th | -91.8%FY2025 · SEC3rd of 527th11th | -107.8%FY2025 · SEC5th of 523rd10th | ———— | -91.8%5 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | 43.5×price Oct 15, 2026 · Market data2nd of 290th97th | ———— | 72.0×price Oct 30, 2026 · Market data1st of 293rd98th | ———— | 57.8×2 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | 1.4×price Oct 15, 2026 · Market data2nd of 428th34th | 0.8×price Oct 30, 2026 · Market data3rd of 415th15th | 0.2×price Oct 30, 2026 · Market data4th of 41st1st | 3.9×price Oct 7, 2026 · Market data1st of 459th70th | 1.1×4 ranked |
| Free cash flow yield (Higher is better) | ———— | ———— | ———— | ———— | -106.5%price Oct 15, 2026 · Market data2nd of 37th3rd | -51.2%price Oct 30, 2026 · Market data1st of 318th7th | ———— | -117.6%price Oct 7, 2026 · Market data3rd of 36th2nd | -106.5%3 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | 1.0×FY2025 · SEConly one with it75th66th | ———— | ———— | ———— | ———— | ———— | 1.0×— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 0 of 1FY2025 · Scorecard7th of 7 | 3 of 10FY2025 · Scorecard1st of 7 | 1 of 8FY2025 · Scorecard6th of 7 | 3 of 14FY2025 · Scorecard3rd of 7 | 2 of 9FY2025 · Scorecard2nd of 7 | 2 of 13FY2025 · Scorecard5th of 7 | 2 of 10FY2025 · Scorecard4th of 7 | 20% passed7 ranked |
| Valuation checks (Higher is better) | —— | —— | —— | —— | 1 of 5FY2025 · Scorecard3rd of 4 | 1 of 4FY2025 · Scorecard1st of 4 | 1 of 4FY2025 · Scorecard1st of 4 | 0 of 4FY2025 · Scorecard4th of 4 | 23% passed4 ranked |
| Growth checks (Higher is better) | —— | —— | 0 of 2FY2025 · Scorecard2nd of 5 | 0 of 2FY2025 · Scorecard2nd of 5 | 0 of 1FY2025 · Scorecard2nd of 5 | —— | 0 of 2FY2025 · Scorecard2nd of 5 | 1 of 2FY2025 · Scorecard1st of 5 | 0% passed5 ranked |
| Profitability checks (Higher is better) | —— | —— | 0 of 3FY2025 · Scorecard1st of 6 | 0 of 3FY2025 · Scorecard1st of 6 | 0 of 3FY2025 · Scorecard1st of 6 | 0 of 3FY2025 · Scorecard1st of 6 | 0 of 3FY2025 · Scorecard1st of 6 | 0 of 2FY2025 · Scorecard1st of 6 | 0% passed6 ranked |
| Financial health checks (Higher is better) | —— | 0 of 1FY2025 · Scorecard7th of 7 | 1 of 3FY2025 · Scorecard4th of 7 | 1 of 2FY2025 · Scorecard1st of 7 | 1 of 3FY2025 · Scorecard4th of 7 | 1 of 2FY2025 · Scorecard1st of 7 | 1 of 3FY2025 · Scorecard4th of 7 | 1 of 2FY2025 · Scorecard1st of 7 | 33% passed7 ranked |
| Shareholder returns checks (Higher is better) | —— | —— | 2 of 2FY2025 · Scorecard1st of 4 | 0 of 1FY2025 · Scorecard3rd of 4 | 1 of 2FY2025 · Scorecard2nd of 4 | —— | 0 of 1FY2025 · Scorecard3rd of 4 | —— | 25% passed4 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | —— | —— | —— | 6.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 4 | 0.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4 | 26.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4 | 1.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 4 | 4.3%4 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | —— | —— | —— | 202026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 4 | 82026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4 | 712026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4 | 132026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 4 | 174 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | —— | —— | —— | +2.0 pp2026-Q2 against 2026-Q1 · 13F1st of 3 | —— | -15.7 pp2026-Q2 against 2026-Q1 · 13F3rd of 3 | +0.7 pp2026-Q2 against 2026-Q1 · 13F2nd of 3 | +0.7 pp3 ranked |
| Dividends | |||||||||
| Shareholder yield (Higher is better) | ———— | ———— | ———— | ———— | 22.9%FY2025 · SEConly one with it98th97th | ———— | ———— | ———— | 22.9%— |
| Dividend per share (Better neither way: ranked highest first) | —— | —— | $0.00FY2025 · SEConly one with it | —— | —— | —— | —— | —— | $0.00— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Athersys: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Brainstorm Cell Therapeutics Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Enzon Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Inhibikase Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Allarity Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Valion Bio, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; aTyr Pharma, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Vyome Holdings, Inc: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Return on equity#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Return on equity | In its sector | In its country |
|---|---|---|---|
| Athersys | — | — | — |
| Brainstorm Cell Therapeutics Inc. | — | — | — |
| Enzon Pharmaceuticals, Inc. | -4.6%FY2025 | 70th percentile in Healthcaremedian -36.9%, 977 companies | 37th percentile in USAmedian 4.8%, 3,580 companies |
| Inhibikase Therapeutics, Inc. | -36.0%FY2025 | 51st percentile in Healthcaremedian -36.9%, 977 companies | 22nd percentile in USAmedian 4.8%, 3,580 companies |
| Allarity Therapeutics, Inc. | -103.8%FY2025 | 24th percentile in Healthcaremedian -36.9%, 977 companies | 10th percentile in USAmedian 4.8%, 3,580 companies |
| Valion Bio, Inc. | -91.8%FY2025 | 27th percentile in Healthcaremedian -36.9%, 977 companies | 11th percentile in USAmedian 4.8%, 3,580 companies |
| aTyr Pharma, Inc. | -107.8%FY2025 | 23rd percentile in Healthcaremedian -36.9%, 977 companies | 10th percentile in USAmedian 4.8%, 3,580 companies |
| Vyome Holdings, Inc | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Athersys | Brainstorm Cell Therapeutics Inc. | Enzon Pharmaceuticals, Inc. | Inhibikase Therapeutics, Inc. | Allarity Therapeutics, Inc. | Valion Bio, Inc. | aTyr Pharma, Inc. | Vyome Holdings, Inc |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | — | — | $0 MSEC1st | — | $0 MSEC2nd | — |
| 2024 | — | — | $0 MSEC4th | — | — | $1 MSEC2nd | $0 MSEC3rd | $8 MSEC1st |
| 2023 | — | — | — | $0 MSEC4th | — | $1 MSEC2nd | $0 MSEC3rd | $9 MSEC1st |
| 2022 | — | — | $0 MSEC5th | $0 MSEC4th | — | $2 MSEC3rd | $10 MSEC2nd | $11 MSEC1st |
| 2021 | — | — | $1 MSEC4th | $3 MSEC2nd | — | $1 MSEC3rd | — | $14 MSEC1st |
| 2020 | — | — | $0 MSEC4th | $1 MSEC3rd | — | — | $10 MSEC2nd | $11 MSEC1st |
| 2019 | $6 MWD1st | — | $0 MSEC4th | — | — | — | $0 MSEC3rd | $3 MSEC2nd |
| 2018 | — | — | $7 MSEC2nd | — | — | — | — | $9 MSEC1st |
| 2017 | — | — | $8 MSEC2nd | — | — | — | — | $10 MSEC1st |
| 2016 | — | — | $8 MSEC1st | — | — | — | — | $3 MSEC2nd |
| 2015 | — | — | $17 MSEC1st | — | — | — | — | $4 MSEC2nd |
| 2014 | — | — | $31 MSEC1st | — | — | — | — | $4 MSEC2nd |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Athersys#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Brainstorm Cell Therapeutics Inc.BCLI · 🇺🇸 USASame industry: Biotechnology · Similar size: $14 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $14 M (last known, Jan 5, 2024)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Enzon Pharmaceuticals, Inc.EZ1.F · 🇺🇸 USASame industry: Biotechnology · Similar size: $14 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $14 M (last known, Jul 30, 2023)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Inhibikase Therapeutics, Inc.IQT.F · 🇺🇸 USASame industry: Biotechnology · Similar size: $14 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $14 M (last known, Dec 25, 2022)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Allarity Therapeutics, Inc.ALLR · 🇺🇸 USASame industry: Biotechnology · Similar size: $14 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $14 M (Oct 15, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Valion Bio, Inc.VBIO · 🇺🇸 USASame industry: Biotechnology · Similar size: $14 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $14 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- aTyr Pharma, Inc.ATYR · 🇺🇸 USASame industry: Biotechnology · Similar size: $14 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $14 M (Oct 30, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Vyome Holdings, IncHIND · 🇺🇸 USASame industry: Biotechnology · Similar size: $14 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $14 M (Oct 7, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- TScan Therapeutics, Inc.TCRX · 🇺🇸 USASame industry: Biotechnology · Similar size: $14 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $14 M (Oct 29, 2026) · revenue $10 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Pasithea Therapeutics Corp.KTTA · 🇺🇸 USASame industry: Biotechnology · Similar size: $15 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $15 M (Oct 26, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Passage Bio, Inc.PASG · 🇺🇸 USASame industry: Biotechnology · Similar size: $15 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $15 M (Aug 1, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- BioVie Inc.BIVI · 🇺🇸 USASame industry: Biotechnology · Similar size: $15 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $15 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- PDS Biotechnology CorporationPDSB · 🇺🇸 USASame industry: Biotechnology · Similar size: $13 M market cap against $14 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $13 M (Aug 1, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.